Character Biosciences is a precision medicine company developing targeted therapies for progressive polygenic diseases, starting with ophthalmology. By integrating genomics, deep clinical data, and AI-driven modeling, Character Bio identifies disease drivers to improve the success rate of drug development. The company is advancing a pipeline focused on dry age-related macular degeneration (AMD) and primary open-angle glaucoma (POAG) to address significant unmet medical needs.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/25/25 | $93,000,000 | Series B |
aMoon Bausch + Lomb Catalio Capital Management Innovation Endeavors Jefferson Life Sciences KdT Ventures Luma Group S32 | undisclosed |
